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Purpose. Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment characterized by redetachment of the retina
as a result of membrane formation and contraction. A variety of retinal cells, including retinal pigment epithelial (RPE) and
M¨ uller glia, and growth factors may be responsible. Platelet-derived growth factor receptor alpha (PDGFRα) is found in large
quantities in PVR membranes, and is intrinsic to the development of PVR in rabbit models. This study explores the expression of
P D G F Ri nc o c u l t u r e so fR P Ea n dM¨ uller cells over time to examine how these two cell types may collaborate in the development
of PVR. We also examine how changes in PDGFRα expression alter M¨ uller cell pathogenicity. Methods. Human MIO-M1 M¨ uller
progenitor (MPC) and ARPE19 cells were studied in a transmembrane coculture system. Immunocytochemistry and Western
blot were used to look at PDGFRα,P D G F R β, and GFAP expression. A transfected MPC line cell line expressing the PDGFRα
(MIO-M1α) was generated, and tested in a rabbit model for its ability to induce PVR. Results. The expression of PDGFRα and
PDGFRβ was upregulated in MIO-M1 MPCs cocultured with ARPE19 cells; GFAP was slightly decreased. Increased expression
of PDGFRα in the MIO-M1 cell line resulted in increased pathogenicity and enhanced ability to induce PVR in a rabbit model.
Conclusions.M¨ uller and RPE cell interaction can lead to upregulation of PDGFRα and increased M¨ uller cell pathogenicity. M¨ uller
cells may play a more active role than previously thought in the development of PVR membranes, particularly when stimulated by
an RPE-cell-rich environment. Additional studies of human samples and in animal models are warranted.
1.Introduction
Proliferative vitreoretinopathy (PVR) occurs in 5–10% of
rhegmatogenous retinal detachments [1]. It is a complex
cellular process characterized by preretinal and subretinal
membrane formation, intraretinal degeneration, gliosis, and
contraction. The disease is characterized by (1) migration
andproliferationofretinalpigmentepithelialcells(RPE)and
glial cells along with synthesis of extracellular matrix (ECM)
proteins, such as collagen or ﬁbronectin, which organize into
retinal and vitreous membranes; (2) intraretinal glial cell
proliferation, photoreceptor degeneration, and disorganiza-
tionofretinalcelllayers[2,3].Inaway,PVRcanbeviewedas
maladaptive and/or aberrant wound healing [4], the severity
of which is often determined by the circumstances in which
it occurs.
Certain clinical characteristics are associated with an
increased risk of PVR development [5, 6]. These can be
classiﬁed into two categories. In the ﬁrst group are risk
factors which increase RPE cell dispersion into the subretinal
andpreretinalspace,andcellularproliferation.Theseinclude
large retinal tears and detachments, cryotherapy and sclera2 Stem Cells International
indentation, and retinal detachments of long duration. In
the second group are characteristics which increase the
presence of growth factors and inﬂammatory cytokines
in the environment, with or without breakdown of the
blood-ocular barrier [7]. This includes vitreous hemorrhage,
choroidal hemorrhage, and cryotherapy. These risk factors
for PVR are additive—the more characteristics, the higher
the risk of PVR development. Patients with traits in both
categories are faced with a perfect storm, in which cell
migrationandproliferationoccurinanenvironmentprimed
for cellular misbehavior.
There has been controversy in the literature regard-
ing the extent of involvement of cells other than RPE,
such as M¨ uller glia, in the pathogenesis of PVR. It is a
fact that M¨ uller cells are active participants. Recent work
demonstrating the reactivity of M¨ uller glia during retinal
detachment and other forms of retinal injury suggests that
these cells play a signiﬁcant role in diseases involving retinal
injury and degeneration, such as PVR. Although RPE cells
have long been considered the principal mediators of this
disease, M¨ uller cell activation, migration, proliferation and
transformation in retinal detachment, and retinal injury
have all been documented [8–10]. Increased expression of
GFAP and vimentin, indicative of increased reactivity, has
been demonstrated in M¨ uller glia in detached human retinas
a n de x p e r i m e n t a lm o d e l so fr e t i n a ld e t a c h m e n t[ 11, 12].
Experimental detachment models have also shown M¨ uller
cell proliferation which peaks at 3-4 days retinal detachment
and continues at a slower rate for weeks to months [13],
as well as migration of M¨ uller cell processes and nuclei
throughout the retinal layers and into the subretinal space
[8]. Certainly, the data supports the need to explore more
closely how these cells participate in PVR pathogenesis, and
what drives them to do so.
The question then arises of whether the behavior of
M¨ uller cells, already primed and activated in the context
of retinal detachment, can be altered by the presence of
RPE cells and growth factors in the vitreous environment.
Our experiments were designed to help us understand how
RPE and M¨ uller cells might aﬀect each other when forced
to interact in the context of retinal detachment, and how
M¨ uller glia altered by this environment participate in PVR.
Because our goal is to better understand this process in
human disease, we have chosen to work with the ARPE19
and MIO-M1 M¨ uller progenitor cell lines.
2. Methods
2.1. Major Reagents. Antibodies against PDGFRα and
PDGFRβ were purchased from Cell Signaling Technology
(Beverly, MA, USA), anti-GFAP from Zymed (San Francisco,
CA,USA),andβ-actinfromAbcam(Cambridge, MA,USA).
Secondary antibodies (antirabbit IgG) were purchased from
Jackson ImmunoResearch Laboratories, Inc (West Grove,
P A,USA).ARPE19cellswerepurchasedfromAmericanT ype
Culture Collection; MIO-M1 M¨ uller progenitor cells (MIIO-
M1 MPCs) were obtained by material transfer agreement
from the Institute of Ophthalmology, University College
London, from Drs. GA Limb and Professor PT Khaw
(patent application PCT/GB2004/005101). Primary rabbit
conjunctival ﬁbroblasts (RCFs) were obtained as previously
described [14].
2.2. Cell Cultures. Transmembrane cell cultures were set up
using MIO-M1 and ARPE19 cells in DMEM/F12 media
with 10%FBS (Gibco). MIO-M1 cells were plated in six-
well plates and allowed to reach conﬂuency. ARPE19 cells
were plated on transwell inserts with 0.4μmp o r e sa n d
allowed to grow to conﬂuency. Upon reaching conﬂuency,
the inserts containing ARPE19 cells were placed in MIIO-M1
containing six-well plates and cultured in a total volume of
3mL of media. Control groups of each single-cell type were
grown concurrently. Cells were fed with 1.5mL of media on
day 2 and 6, with complete media changes at day 4.
2.3. Western Blotting. MIO-M1 and ARPE19 cells were
h a r v e s t e da td a y s1 ,3 ,5 ,a n d7 .L y s a t e sw e r em a d ef o r
Western blot analysis. Media was removed and cells were
collected from experimental and control plates and inserts
using sterile cell scrapers in PBS. Lysates of these cells were
createdbyincubationfor30minat4◦CinRipabuﬀer50mM
Tris HCl [pH 8.0], 0.1% SDS, 0.5% sodium deoxycholate,
1% NP-40, 150mM NaCl, 2% protease inhibitor cocktail,
2% phosphatase inhibitor cocktail 1, and 2% phosphatase
inhibitor cocktail 2 (Sigma), followed by 15 seconds of
sonication and removal of cellular debris by centrifugation
at 12,000rpm for 12min at 4◦C. The protein content of
the lysates was determined with the BCA protein assay
(Thermo Scientiﬁc). Expression of PDGFRα and PDGFRβ
in the control and experimental samples was compared by
Western blotting. 50μg of protein was resolved by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The protein bands were transferred onto
nitrocellulose membranes (Bio-Rad Laboratories), and the
membrane was subjected to Western blot analysis using anti-
PDGFRα or anti-PDGFRβ primary antibodies. Band density
was quantiﬁed using Image J and normalized to β-actin
expression.
2.4. Immunocytochemistry. MIO-M1 and ARPE19 cells were
cocultured as described above on 16-well glass slides with
ARPE19 cells in 8-well strips of 0.2μm membrane inserts.
Inserts were removed after 5 days and the plated cells
were ﬁxed for 20 minutes with 4% paraformaldehyde and
permeabilized for one hour at room temperature with
10% goat serum and 0.1% Triton X-100 in PBS. MIO-
M1 cells were stained with primary antibodies directed
against PDGFRα, PDGFRβ, and incubated at 4◦C overnight.
Primary and secondary antibodies were prepared in 10% GS
in PBS solutions at a concentration of 1:100 for PDGFRα
and β. The slides were then washed with PBS. Secondary
antibodies were added to the slides for 1 hour. Slides
were then washed with PBS, coated with mounting media
containing DAPI, and covered. The cells were examined by
ﬂuorescent microscopy with Cy2 ﬁlter.
2.5. Preparation of MIO-M1α Cell Line and Rabbit Model
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Figure 1:ImmunocytochemicalstainingforPDGFRαandβ(green)inMIO-M1MPCs.ExpressionofPDGFRαafter5dayswhencocultured




progenitor cells (MIO-M1 MPCs). Transfected cells with
increased PDGFRα expression were selected for resistance to
histidinol toxicity and designated as MIO-M1α.
PVR was induced in the right eyes of pigmented rabbits
purchased from Covance (Denver, PA, USA). Brieﬂy, a gas
vitrectomy was performed by injecting 0.1mL of perﬂuo-
ropropane (C3F8) (Alcon, Fort Worth, TX, USA) into the
vitreous cavity 4mm posterior to the corneal limbus. One
week later, all rabbits received two injections: (1) 0.1mL of
PRP (platelet-rich plasma) and (2) 0.1mL DMEM contain-
ing 2 × 105 of rabbit conjunctival ﬁbroblasts (RCFs), MIO-
M1, and MIO-M1α cells. The extent of retinal detachment
was evaluated by indirect ophthalmoscopy with a handheld
+30 D fundus lens at days 2, 4, 7, and weekly thereafter for a
total of 4 weeks. Extent of PVR was graded according to the
Fastenbergclassiﬁcationfromgrade0through5[15].Onday
28 the animals were sacriﬁced and the eyes were enucleated.
All surgeries were performed under aseptic conditions and
pursuant to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The protocol for the use
of animals was approved by the Schepens Animal Care and
Use Committee. Mann-Whitney test for nonparametric data
(P<0.05) was used for statistical analysis.
3. Results
As previously discussed, the goal of these experiments is to
determine if RPE cells induce a change in Muller cells that
would result in a PVR-inducing cell.
Immunocytochemical staining of MIO-M1 MPCs after
5 days of coculture with ARPE19 cells conﬁrms MIO-M1
MPCs upregulate their expression of PDGFRα (Figures 1(a)-
1(b)), with a moderate increase in expression of PDGFRβ
(Figures 1(c)-1(d)). Consistent with these results, Western
blot analysis showed upregulation of PDGFRα expression
in experimental MIO-M1 MPCs by day 5 after-plating
(Figure 2). In contrast, expression of PDGFRβ remained
low in MIO-M1 and ARPE 19 cells across the same time,
with a measurable increase in MIO-M1 cells by day 7
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Figure 2: Western blot analysis of coculture samples at days 1, 3, 5, and 7 shows noticeable increases in PDGFRα expression in MIO-M1
MPCs. Transfected ARPE19 cells with increased expression of PDGFRα (RPEα) are used as control for comparison. PDGFRβ levels remain
relatively low in both cell types throughout the course of the experiment, with a small increase in MIO-M1 MPCs on day 5 and a more
signiﬁcant increase by day 7. MIO-M1 cells show a small but measurable and consistent decrease in expression of GFAP between days 1 and
7 of the experiment. RPEα cells are included for control. Protein concentrations were standardized by Bradford assay. Band intensity was
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Figure 3: Western blot of ARPE19, ARPE19α,M I O - M 1M P C s ,
MIO-M1α-transfected MPCs, and rabbit conjunctival ﬁbroblast
(RCF) lysates shows comparable expression of PDGFRα in trans-
fected MPCs (MIO-M1α) and RCFs, with levels comparable to
those developed in cocultured cells. MIO-M1α MPCs have an
approximate 2.56X increase in PGFRα expression when compared
to untransfected MIO-M1 MPCs, and a 1.65X increase in expres-
sion when compared to RCFs. Relative expression ratios are shown.
e x p r e s s i o nw a so b s e rv e di nM I I O - M 1M P C sa se a r l ya sd a y3
after coculture (Figure 2).
The above data suggests that upregulation of PDGFRα
could lead to stimulation of ﬁbroblastic behavior consistent
with PVR in M¨ uller cells. Given our knowledge of the
importance of PDGFRα and not PDGFRβ (see discussion
below), we overexpressed PDGFRα in MIO-M1 MPCs to
test our hypothesis that M¨ uller cells alone can induce
PVR. As conﬁrmed by Western blot analysis, transfection
of MIO-M1 cells with pLHDCX2-PDGFRα resulted in
increased expression of PDGFRα (Figure 3) in MIO-M1 cells
comparabletothatobservedincellscoculturedwithARPE19
and with the expression of rabbit conjunctival ﬁbroblasts
(RCFs). Comparison of MIO-M1, MIIO-M1α,a n dR C F
behavior in a rabbit model showed a dramatic increase in
PVR pathogenicity of the MIIO-M1α cell line comparable to
that of RCF’s. MIIO-M1α cells were equally eﬀective as RCFs
in inducing PVR after-transplantation (Figure 4).
4. Discussion
PDGFRα has long been implicated in the pathogenesis of
PVR. It is found extensively in preretinal membranes from
PVR patients [16, 17]. Experimental models using mouse
embryonic ﬁbroblasts as well as rabbit conjunctival ﬁbrob-
lasts have demonstrated the intrinsic role that PDGFRα,
and not PDGFRβ, plays in the pathogenesis of the disease
[14, 18]. In fact, inhibition of the PDGFRα, either through
inhibitionofitstyrosinekinaseortheROSpathway,hasbeen
shown to be suﬃcient in these models to attenuate and/or
inhibit the development of PVR [19, 20].
Studies show that M¨ uller cells are present in PVR
membranes [21]. However, RPE rather than M¨ uller cells,
have dominated the literature and have been the focus of
most studies and theories of PVR [22, 23]. This is partly due
to the fact that RPE cell markers are more abundant in PVR
membranes.TheassumptionhasbeenmadethatM¨ ullercells
play a less important role, yet this may not be the case.
Our in-vitro study observations and correlating rabbit
model results suggest that one of the mechanisms by which
M¨ uller cells may play a role in PVR is by upregulating
the expression of PDGFRα. When comparing with previous
studies in the literature, this change has a bigger impact
on M¨ uller cell behavior than RPE cell behavior [24]. These
experiments also suggest that M¨ uller cell up-regulation of
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Figure 4: Overexpression of PDGFRα in MIO-M1 MPCs induces
a phenotypic switch to ﬁbroblast-like cells that eﬀectively induce
PVR postintravitreal injection in rabbit. Classiﬁcation is as follows:
stage 0—no PVR; stage 1—presence of ﬁbrous bands; stage 2—
ﬁbrous bands with traction; stage 3—retinal detachment involving
less than 2 quadrants; stage 4—retinal detachment involving
more than 2 quadrants; stage 5—total retinal detachment. For
statistical purposes, stage 3 or higher is considered severe PVR.
Mann-Whitney statistical analysis for nonparametric data showed
a statistically signiﬁcant diﬀerence (P<0.05) at all three time
points between RCFs versus MIO-M1 MPCs, and MIO-M1 MPCs
versus MIO-M1α MPCs. No statistically signiﬁcant diﬀerence was
observed between RFCs versus MIO-M1α MPCs.
rich environment which exists in retinal detachments with
high-risk characteristics. High-risk retinal detachments for
the development of PVR are more commonly characterized
by increased RPE cell migration and presence in the vitreous
cavity. In the presence of RPE cells in our study, M¨ uller
progenitor cells do two very important things—they change
their expression of traditional M¨ uller cell markers such as
GFAP, and they increase their expression of PDGFR. Though
these changes do not appear to be signiﬁcant at ﬁrst glance,
studies in the rabbit model suggest that only a small increase
in PDGFRα expression is necessary to dramatically alter the
behavior of these cells to resemble that of ﬁbroblasts. This
is in stark contrast to studies performed using RPE cells, in
which a more than 80-fold increase in receptor expression
wasnecessarytosigniﬁcantlyaltertheirbehavior,withinvivo
results which were still inferior when compared to those
using ﬁbroblasts [24].
M¨ ullercellplasticityandtheircapacitytotransformtheir
phenotype have already been demonstrated [25, 26]. The
ability of this cell type to alter its expression of GFAP in
diﬀerent environments helps to support our observations
[9]. Dediﬀerentiation in particular is thought to play an
importantroleinhowM¨ ullercellsparticipateinPVR.M¨ uller
cells in the peripheral retina, where PVR most often occurs,
have been shown to express stem cell markers, indicative
of active proliferation, and dediﬀerentiation [27]. In-vitro,
human-derived M¨ uller cells, including the MIO-M1 M¨ uller
progenitor cell line, have been shown to exhibit neural stem
cell traits [28, 29].
We therefore propose the following theory to PVR
development invivo. During retinal detachment, depending
on the size and longevity of the detachment as well as the size
and location of the retinal tear, there is an opportunity for
RPE cells to abandon their natural monolayer and migrate
onto the subretinal and preretinal space. The vitreous often
acts as a scaﬀold onto which these cells can attach. Once
allowed to migrate, RPE cells begin to produce cytokines
and cofactors (yet to be fully identiﬁed) which can alter
M¨ uller cell phenotype and growth factor surface protein
expression,leadingtoanincreaseinﬁbroblasticbehaviorand
pathogenicity. Whether there is complete transformation of
M¨ uller cells invivo remains a question. It is possible that
the abundance of RPE cells in PVR membranes is a “red-
herring”, and that RPE cells play more of an eﬀector role,
with M¨ uller cells doing most of the membrane formation
and contraction.
The drawback of our study is that it is based on observa-
tions in an in-vitro setup and a limited rabbit animal model.
These observations would be more diﬃcult to make invivo,
given the progressive and dynamic nature of the disease and
the plasticity of M¨ uller cells. Despite its limitations, our in-
vitro model allows us to capture speciﬁc changes, and our
rabbit model allows us to conﬁrm their importance.
Certainly more work needs to be performed invivo.
The next step would be a series of experiments in reti-
nal detachment models looking at intraretinal GFAP and
PDGFRα expression. Another set of experiments would be
aimed at identifying those molecules which trigger M¨ uller
cell transformation and growth factor receptor expression.
Once identiﬁed, therapeutic interventions can be designed
to interfere with and redirect this process.
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